{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-25-000136","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.575676+00:00","generated_at":"2026-05-17T19:32:43.767742+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arvinas Q2 2025: NDA for vepdegestrant; CEO to retire; cash $861M","bullets":["Submitted NDA to FDA for vepdegestrant in ESR1m ER+/HER2- advanced breast cancer.","VERITAC-2 Phase 3: 2.9-month PFS improvement in ESR1m subgroup; ITT not significant.","Cash $861.2M at June 30, 2025 (down from $1,039.4M); R&D $68.6M Q2 vs $93.7M YoY.","CEO John Houston to retire; board searching for successor; remains Chair.","ARV-102 Phase 1: >50% LRRK2 reduction in CSF, >90% in PBMCs; dosing in Parkinson's."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-25-000136","json":"https://secwatch.observer/filing/0001655759-25-000136.json","markdown":"https://secwatch.observer/filing/0001655759-25-000136.md","text":"https://secwatch.observer/filing/0001655759-25-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/0001655759-25-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/arvn-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:32:43.767742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}